An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin
Status:
Completed
Trial end date:
2017-11-30
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to investigate cardiovascular safety of gemigliptin by
evaluating the time until patients report with major adverse cardiovascular events (MACE) in
T2DM patients treated with gemigliptin.
Study patients will be followed up to 4 years until MACE occurrence or until the patient
drops out of the study or completion of the study. The patient who switches to a
non-gemigliptin treatment after initiating gemigliptin therapy will be followed until MACE
occurrence or until the patient drops out of the study or completion of the study.
The secondary objectives of the study are to evaluate adverse events related as well as
not-related to MACE in diabetic patients treated with gemigliptin.